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BACKGROUND: Polycystic ovary syndrome (PCOS), a common reproductive endocrinologic disorder in woman, was considered to be related 
to sleep disturbance. This study is aimed to analyze the 
correlation between excess androgen markers and Athens 
Insomnia Scale (AIS) in PCOS.
METHODS: This observational, cross-sectional study 
of PCOS was conducted to 31 subjects to evaluate the 
correlation between serum total testosterone, sex hormone 
binding globulin (SHBG) and free androgen index with the 
incidence of sleep disturbance using AIS. Sleep disturbance 
was present if the score ≥6. The correlation between excess 
androgen markers and sleep disturbance was analyzed using 
Pearson’s coefficient of correlation or Spearman’s rho test. 
Correlation coefficient more than 0.5 with p<0.05 was 
considered significant.
RESULTS:  Out of 31 PCOS subjects aged 20-40 years, 
39% subjects had AIS score ≥6. Mean serum testosterone 
in AIS score >6 group was higher than AIS score <6 group 
but not statistically significant (46.68 vs. 28.49 ng/mL, 
p>0.05). No significant correlation was found between 
serum total testosterone, SHBG and free androgen index 
with AIS score. After adjusting for AIS score, there was 
the moderate positive  correlation  between  serum  total 
testosterone  level although  not  statistically  significant 
(r=0.54,  p=0.07). 
CONCLUSION:  The  serum  total  testosterone  level 
might influence  the  occurrence  of  sleep  disturbance  in 
PCOS.
KEywORDS: PCOS, androgen excess, testosterone, sleep 
disturbance, Athens Insomnia Scale
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Abstract
Introduction
Polycystic ovary syndrome (PCOS) is a common 
reproductive endocrinologic disorder which could be found 
in 4-20% premenopausal women, depending on the criteria 
used.(1-3) This condition is characterized by oligo- or 
anovulation, the manifestation of hyperandrogenism, and 
polycystic ovarian morphology. The pathophysiology is still 
unclear, however, insulin resistance and hyperandrogenism 
may play important role.(3-5) Insulin resistance found 
in PCOS is related to increased serum testosterone and 
decreased sex-hormone binding globulin (SHBG) level. This 
may lead to the occurrence of several clinical manifestations 
due to androgen excess condition (hirsutism, alopecia, and 
obesity). Obesity may be found in approximately 60% PCOS 
women and subject to the occurrence of sleep disturbance. 
Furthermore, the stressful condition caused by PCOS such 
as menstrual disturbance and infertility may aggravate the 
possibility of sleep disturbance.(3,6,7) 
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 Several studies revealed the presence of sleep 
disturbance in PCOS, such as excessive daytime sleepiness 
and  increased  obstructive  sleep  apnea  (OSA).  The 
exact mechanism  of  these  conditions  are  not  fully 
understood,   but  alterations  in  body  fat  composition  may 
be  the  possible cause. Furthermore, sleep disturbance may 
decrease life quality and probably cause future metabolic 
disorders.(7-10) To assess sleep disturbance, several tools 
have been developed.  Soldatos, et al., have created a brief, 
eight  question  instruments  named  Athens  Insomnia  Scale 
(AIS)  based  on  the  International  Statistical  Classification 
of  Disease  and  Related  Health  Problem  10th  revision 
(ICD-10) criteria for sleep disorders. This instrument  has 
been  validated   and   widely   used   as  a  tool  to  detect 
the  presence  of   sleep  disturbance  in  wide  populations.
(7,11,12) 
  Although some studies have found the correlation 
between PCOS and sleep disturbance (7-9,13-15), but data 
showing the correlation between serum total testosterone, 
SHBG and free androgen index as markers for androgen 
excess with AIS score are lacking. This study is aimed to 
analyze the correlation between those excess androgen 
markers  and  the  occurrence  of  sleep  disorder  in  PCOS 
using AIS.
Methods
Study Design
This observational cross-sectional study was conducted 
to 31 PCOS subjects aged 20-40 years who presented to 
Assisted Reproductive Unit/Aster Fertility Clinic, Hasan 
Sadikin Hospital Bandung. The local ethics committee has 
approved the study protocol, with ethical approval LB.04.01/
A05/EC/110/IV/2017 given from The Ethics Committee for 
Health Research Hasan Sadikin Hospital. 
Inclusion and Exclusion Criteria
The PCOS was diagnosed using Rotterdam Consensus 
on Diagnosis Criteria for PCOS. The diagnosis of PCOS 
was when at least two of these three following conditions 
were found: 1) oligo- and/or anovulation; 2) clinical and/or 
biochemical signs of hyperandrogenism; and 3) polycystic 
ovaries  and  exclusion  of  other  etiologies, such  as 
congenital  adrenal  hyperplasia,  androgen-secreting tumors 
or Cushing’s syndrome.(16) Subjects who smoke, alcoholics, 
drink  coffee  more  than  400 mL,  were  excluded  from the 
study,  as well  as  subjects  who  used  sedative,  metformin, 
corticosteroid, and hormonal contraceptive. 
Subjects’ Measurement
All subjects received detailed study information and 
had given consent before participating in this study. 
Anthropometric measurement and body mass index 
calculation were conducted, followed by filling the AIS 
questionnaire by all subjects. Ten milliliters of peripheral 
vein blood was collected from all subjects for total serum 
testosterone, SHBG, and free androgen index assay. Normal 
values for those excess androgen markers in premenopausal 
women are: serum total testosterone 8.40-48.1 ng/dL, SHBG 
26.1-110 nmol/L and free-androgen index 0.51-6.53%.(17)
 The AIS is a brief questionnaire consists of 8 question 
to assess the presence of sleep disturbance. Each question has 
value range 0-3, with 0 interpreted as no disturbance and 3 
as severe problem. Subjects were asked to answer questions 
in AIS related to sleep disturbance that perceived at least 3 
times in a week in the last month. The total sum of the score 
was interpreted as follow: score less than 6 indicated there 
was no sleep disturbance, and score more than or equal to 6 
indicated the presence of sleep disturbance.(11,12)
Statistical Analysis
Data were analyzed using Statistical Package for Social 
Science (SPSS, IBM Co.) version 24. Quantitative data were 
presented in mean±standard deviation, while qualitative 
data were presented in amount and percentage. To analyze 
the correlation between total serum testosterone, SHBG and 
free androgen index with AIS score, Pearson’s correlation 
coefficient test was conducted if data was normally 
distributed. If the data were not normally distributed or 
data transformation was not successful, nonparametric 
Spearman’s rho test was used. The correlation coefficient 
>0.5 with p value <0.05 was considered significant.
Results
The characteristics of subjects were listed in Table 1. All 
subjects were infertile and 61% were oligomenorrheic. The 
body mass index mean was 31.21 kg/m2, with 55% subjects 
had body mass index (BMI) more than 30 kg/m2. Serum 
total testosterone, SHBG, and free-androgen index level 
were still in normal range. AIS score median was 4 and 61% 
of subjects had AIS score >6, which  indicated  the  presence 
of  sleep disturbance. 
 Meanwhile the correlation analysis of variables with 
AIS score were shown in Table 2. From Table 2, no significant 
correlations were found between age, BMI, SHBG level and 
free-androgen index with AIS score. However, there was 
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Table 1. Characteristics of study subjects.
Characteristics Results*
Age (years) 30.19±3.67
Body weight (kg) 75.99±15.19
Height (cm) 156.10±4.74
BMI (kg/m2) 31.21±6.17
18.5-24.9 4(13)
25-29.9 10(32)
≥30 17(55)
Menstrual cycle (days)
24-38 12(39)
>38 19(61)
Type of infertility
Primary 30(97)
Secondary 1(3)
Serum total testosterone (ng/mL) 26.53(4.80-159.00)
SHBG (nmol/L) 18.67(6.37-102.70)
Free-androgen index (%) 4.32(0.42-22.18)
AIS score median 4(0-14)
Subjects with score <6 19(61)
Subjects with score ≥6 12(39)
*Numeric variables with normal distributions were presented in mean±standard 
deviation. Numeric variables with non-normal distributions were presented in 
median (minimum-maximum). Categorical variables were presented in n(%).
Table 2. Correlation analysis of study variables with AIS score.
Variables
Age (years) r = -0.182
p  = 0.328
n = 31
BMI (kg/m2) r = 0.099
p  = 0.597
n = 31
Serum total testosterone (ng/mL) r = 0.326
p  = 0.074
n = 31
SHBG (nmol/L) r = 0.198
p  = 0.285
n = 31
Free-androgen index r = 0.166
p  = 0.373
n = 31
*Pearson correlation coefficient test
AIS score*
Table 3. The correlation between serum total testosterone level 
and AIS score.
AIS score 
group
Serum total 
testosterone level 
mean (ng/mL)
Correlation 
coefficient* p value
≥6 46.68 r = 0.54 0.07
<6 28.49 r = -0.4 0.09
*Spearman’s rho test
Discussion
PCOS characterized clinically by the presence of oligo- or 
anovulation, infertility, hyperandrogenic manifestation, and 
metabolic disorders such as obesity. Anovulation is 80% 
caused by PCOS, making it the leading cause of women 
infertility and may clinically suspected by the presence of 
menstrual disorders.(16) Menstrual irregularity is a hallmark 
of anovulation (18,19), and this was found in this study. 
All subjects were infertile and 61.29% complained about 
oligomenorrhea, which in turn, which reflects anovulation.  
 Hyperandrogenism is considered an important aspect 
in PCOS’ pathophysiology. This condition might be detected 
using clinical examination or using laboratory evaluation of 
excess androgen markers. The common methods to detect 
hyperandrogenism is to evaluate serum free testosterone 
and SHBG level, and calculation of free androgen index.
(20-22) Hyperandrogenism could manifest as high serum 
testosterone level or biological activity, low SHBG 
resulting increased level of free sex steroid hormones, and 
elevated free androgen index. According to Rosner, et al., 
free androgen  index  is  a  unitless  quotient  of  serum 
testosterone level divided by serum SHBG level, and it can 
be served as a surrogate marker to evaluate free testosterone 
biologic activity. It was a simple and good correlation with 
physical separation measures in women.(20) Furthermore, 
the role of serum testosterone in sleep disturbances has been 
analyzed in several studies. Androgenic receptors were 
abundantly present in the suprachiasmatic nucleus (SCN), 
suggesting the role of testosterone in modulating sleep 
physiology.(23,24)
 The mean serum total testosterone, SHBG and free 
androgen index level were in normal range in this study. 
Elevated circulating androgens were present in 60-80% of 
women with PCOS.(22) Hence, androgen excess markers 
only may not reflect directly the hyperandrogenic condition 
occurred in PCOS. High BMI and menstrual irregularities, 
in turn, may represent the effect of hyperandrogenic state 
found in PCOS.(3,25,26)
a weak correlation between serum total testosterone level 
with AIS score although not reached significance (r=0.326; 
p>0.05). 
 After adjusting the AIS score, analysis of the 
correlation between serum total testosterone level and AIS 
score were presented in Table 3. In AIS score >6 group, 
the moderate correlation was found although not reached 
significance level (r=0.54; p>0.05).
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  The clinical symptoms caused by PCOS may affect the 
patient's biopsychosocial life. Women with PCOS have an 
increased of anxiety and affective disorders, which in turn 
with  coexisting  hormonal  imbalance  may  lead  to  sleep 
disturbance. Using AIS, there were 39% subjects whose 
score >6 which indicates the presence of sleep disturbance. 
Franik, et al., reported there was 12.6% clinically significant 
insomnia  of  their  study  subjects  who  complained  about 
sleep disturbance. Furthermore, they also found shorter 
duration of sleep, and high prevalence of difficulties in 
falling asleep.They also conclude that screening of sleep 
disturbance  should  be  a  part  of  medical  diagnosis  in 
PCOS.(7) 
 Sleep disturbance in PCOS has been studied 
extensively in last decade. Vgontzas and colleagues found 
30 times higher risk of developing obstructive OSA in PCOS 
women.(9) The incidence of OSA in PCOS may increase 
due to alterations in sex steroids (i.e., high androgen and 
low estrogen levels) and increased visceral adiposity.(8) 
Another form of sleep disturbance was excessive daytime 
sleepiness and insomnia.(7,13) In a larger population 
consisting 724 PCOS women, sleep disturbance was twice 
as common in women with PCOS compared with women 
without PCOS. Furthermore, they also found increasing 
occurrence of difficulties in falling asleep.(13) 
 Another possible explanation for high incidence of 
sleep disorder in PCOS was its relationship with increased 
abdominal visceral obesity caused by hyperandrogenemia 
and insulin resistance. Those conditions may alter chest 
wall and upper airway movement that may lead to a 
reduction of the functional residual capacity of the lung and 
increased sleep apnea.(15) Those were in line with subjects 
characteristics in the present study. The majority of the 
subjects (55%) were obese, which in turn, predispose them 
to a higher risk of sleep disturbance. On the other hand, 
other study reported no increase of having OSA in non-
obese PCOS women.(27) 
 No significant correlation exists between subjects’ 
characteristics and excess androgen markers with AIS score 
in this study. After adjusting the AIS score, subjects in AIS 
score >6 group have a moderate correlation between serum 
total testosterone level with AIS score. The mean serum total 
testosterone level in this group was higher than those in AIS 
score <6 group (46.68 vs. 28.49 ng/mL, p>0.05). Although 
not reaching statistical significance, this may reflect the role 
of testosterone in sleep physiology. In mammals, the central 
control of circadian rhythm was done by SCN, which is 
lying above optic chiasma. However, the exact mechanism 
how SCN controls the sleep-wake cycle and creating sleep 
architecture are still unclear, but it was believed that SCN 
regulates circadian timing in physiology and behavior by 
sending outputs to the another neuroendocrine systems. 
Androgen receptors were abundantly found in SCN, hence 
androgenic effects were also important in maintaining 
circadian timing.(24) 
 Sleep disturbance now recognized as a determinant 
factor in women health, especially in the context of 
menstrual cycle and fertility. Kloss, et al., in their review 
stated  that  stress  may  affect  fertility  and  as  well  as 
chronic  insomnia  to  the  extent  it  produces  a  stress 
response.(28)
 The limitation of this study was the study subjects 
only consist of PCOS subjects without control from normal, 
ovulatory women. The limited, small amount sample also 
may lead to non-significant results in statistical analysis. 
Since we did not have further data of insulin resistance, 
the in-depth analysis regarding this condition to sleep 
disturbance mechanism was not possible. The research 
regarding the circadian rhythm that might be affected by 
the androgen excess condition in PCOS warrants further 
exploration. 
 Data regarding sleep pattern throughout menstrual 
cycle is very limited.  In the healthy, ovulating women, 
the sleep homestasis and quality remains stable at different 
menstrual phases. However, there were some changes 
in sleep pattern that may subject for further evaluation.
(29) Since PCOS was mainly correlated with anovulation, 
this condition  might  be  explored  further.  Thus, several 
aspects  i.e.,  interaction  of  androgens  with  other 
hormones especially  melatonin  who  plays  important  role 
in sleep and circadian rhythm in PCOS women also might 
be analyzed. 
Conclusion
In general, detection and treatment of sleep disturbance 
in infertile population (especially PCOS), should be an 
integral part of the management. Clinicians who manage 
PCOS should become well-informed that besides the 
established clinical feature, there is another side of 
management that should be carefully explored in order to 
provide comprehensive management of PCOS. This indeed 
may affect biopsychosocial aspects of PCOS management. 
Furthermore, serum total testosterone level might influence 
the occurrence of sleep disturbance in PCOS.
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